Burning Rock Biotech Limited - American Depositary Shares (BNR)

Competitors to Burning Rock Biotech Limited - American Depositary Shares (BNR)

Biocept

Biocept operates in the liquid biopsy market like Burning Rock Biotech, focusing on providing diagnostic tests for oncology. Both companies are developing tests based on circulating tumor DNA (ctDNA) analysis, but Biocept has strategically positioned itself by offering proprietary, patented technologies that could set it apart. While both are competing for similar market share, Burning Rock may have a slight edge in established relationships with healthcare providers in the Asian market.

Foundation Medicine

Foundation Medicine offers comprehensive genomic profiling services that help oncologists make treatment decisions based on a patient's specific cancer genetics. It competes with Burning Rock Biotech by providing extensive data sets and extensive clinical research to support its test offerings. Foundation Medicine's backing by Roche and a wide array of collaboration projects give it a significant competitive advantage over Burning Rock in the overall diagnostic space.

Freenome

Freenome is another player in the space of liquid biopsy and colorectal cancer screening, utilizing machine learning and multiomics to improve early detection. While Burning Rock specializes in various cancers and liquid biopsy applications, Freenome's focus on AI-driven diagnostics allows it to innovate rapidly in cancer screening. The advanced technology and access to large datasets provide Freenome with a competitive advantage in early cancer detection compared to Burning Rock.

Guardant Health 

Guardant Health specializes in non-invasive cancer diagnostics using liquid biopsy technology, similar to Burning Rock Biotech. Both companies focus on genomic profiling to identify cancer mutations and guide treatment decisions for oncology patients. However, Guardant Health has established a strong brand presence, extensive clinical validation, and partnerships that enhance its market reach, which currently gives it a competitive advantage in the liquid biopsy segment.